title: Phenol sulfotransferases: hormonal regulation, polymorphism, and age of onset of breast cancer.
abstract: In recent years, significant effort has been made to identify genes that influence breast cancer risk. Because the high-penetrance breast cancer susceptibility genes BRCA1 and 2 play a role only in a small fraction of breast cancer cases, understanding the genetic risk of the majority of breast cancers will require the identification and analysis of several lower penetrance genes. The estrogen-signaling pathway plays a crucial role in the pathophysiology of breast cancer; therefore, polymorphism in genes involved in this pathway is likely to influence breast cancer risk. Our detailed analysis of gene expression profiles of estrogen- and 4-OH-tamoxifen-treated ZR75-1 breast cancer cells identified members of the sulfotransferase 1A (SULT1A) phenol sulfotransferase family as downstream targets of tamoxifen. On the basis of the induction of SULT1A by 4-OH-tamoxifen and the known inherited variability in SULT1A enzymatic activity, we hypothesized that polymorphism in sulfotransferase genes might influence the risk of breast cancer. Using an RFLP that distinguishes an arginine to histidine change in exon 7 of the SULT1A1 gene, we characterized SULT1A1 genotypes in relation to breast cancer risk. An analysis of 444 breast cancer patients and 227 controls revealed no effect of SULT1A1 genotype on the risk of breast cancer (P = 0.69); however, it did appear to influence the age of onset among early-onset affected patients (P = 0.04). Moreover, individuals with the higher activity SULT1A1*1 allele were more likely to have other tumors in addition to breast cancer (P = 0.004; odds ratio, 3.02; 95% confidence interval, 1.32, 8.09). The large number of environmental mutagens and carcinogens activated by sulfotransferases and the high frequency of the SULT1A1*1 allele in human populations warrants additional studies to address the role of SULT genes in human cancer.
authors.affiliation: Departent of Adult Oncology, Dana Farher Cancer Institute, Boston, Massachasetts 02115, USA.
authors.forename: P
authors.initials: P
authors.lastname: Seth
authors.forename: K L
authors.initials: KL
authors.lastname: Lunetta
authors.forename: D W
authors.initials: DW
authors.lastname: Bell
authors.forename: H
authors.initials: H
authors.lastname: Gray
authors.forename: S M
authors.initials: SM
authors.lastname: Nasser
authors.forename: E
authors.initials: E
authors.lastname: Rhei
authors.forename: C M
authors.initials: CM
authors.lastname: Kaelin
authors.forename: D J
authors.initials: DJ
authors.lastname: Iglehart
authors.forename: J R
authors.initials: JR
authors.lastname: Marks
authors.forename: J E
authors.initials: JE
authors.lastname: Garber
authors.forename: D A
authors.initials: DA
authors.lastname: Haber
authors.forename: K
authors.initials: K
authors.lastname: Polyak
mesh_terms: D000328:Adult; D017668:Age of Onset; D000483:Alleles; D001120:Arginine / Q000737:chemistry; D015239:Arylsulfotransferase / Q000235:genetics* / Q000378:metabolism*; D015152:Blotting, Northern; D001943:Breast Neoplasms / Q000201:enzymology* / Q000235:genetics*; D016022:Case-Control Studies; D004967:Estrogens / Q000494:pharmacology; D005091:Exons; D005260:Female; D005838:Genotype; D006639:Histidine / Q000737:chemistry; D006801:Humans; D015151:Immunoblotting; D008875:Middle Aged; D016133:Polymerase Chain Reaction; D011110:Polymorphism, Genetic; D012150:Polymorphism, Restriction Fragment Length; D012333:RNA, Messenger / Q000378:metabolism; D020133:Reverse Transcriptase Polymerase Chain Reaction; D012307:Risk Factors; D013629:Tamoxifen / Q000494:pharmacology; D014407:Tumor Cells, Cultured
chemical_list: D004967:Estrogens; D012333:RNA, Messenger; D013629:Tamoxifen; D006639:Histidine; D001120:Arginine; D015239:Arylsulfotransferase